Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Cushman

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|August 27, 2003
Roundtable discussion: the ALLHAT trialMarvin Moser, William Cushman, Michael Weber
Journal of Clinical Hypertension (Greenwich, Conn.)|June 9, 2006
Resistant or difficult-to-treat hypertensionMarvin Moser, William Cushman, Joel Handler
Journal of Clinical Hypertension (Greenwich, Conn.)|August 17, 2005
Hypertension, renal disease, and cardiovascular outcomesMarvin Moser, Jan Basile, William Cushman
Journal of Clinical Hypertension (Greenwich, Conn.)|May 9, 2007
The ALLHAT study revisited: do newer data from this trial and others indicate changes in treatment guidelines?Marvin Moser, Suzanne Oparil, William Cushman, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 11, 2008
Diuretics as monotherapy or as part of combination therapy for hypertension: an updateMarvin Moser, Domenic Sica, William Cushman, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|September 8, 2011
Thiazide and loop diureticsDomenic A Sica, Barry Carter, William Cushman, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|August 4, 2007
Getting to goal blood pressure: why reserpine deserves a second lookJoshua Barzilay, Richard Grimm, William Cushman, et al.
Journal of Diabetes and Its Complications|August 25, 2022
A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: A revisit to the ACCORD trialHamed Kianmehr, Jingchuan Guo, Yilu Lin, et al.
American Journal of Nephrology|December 20, 2016
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes StudyVasilios Papademetriou, Laura Lovato, Costas Tsioufis, et al.
Diabetes Care|December 15, 2012
Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trialHertzel C Gerstein, Walter T Ambrosius, Ronald Danis, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Clinical Hypertension (Greenwich, Conn.)|August 27, 2003
Roundtable discussion: the ALLHAT trialMarvin Moser, William Cushman, Michael Weber
Journal of Clinical Hypertension (Greenwich, Conn.)|June 9, 2006
Resistant or difficult-to-treat hypertensionMarvin Moser, William Cushman, Joel Handler
Journal of Clinical Hypertension (Greenwich, Conn.)|August 17, 2005
Hypertension, renal disease, and cardiovascular outcomesMarvin Moser, Jan Basile, William Cushman
Journal of Clinical Hypertension (Greenwich, Conn.)|May 9, 2007
The ALLHAT study revisited: do newer data from this trial and others indicate changes in treatment guidelines?Marvin Moser, Suzanne Oparil, William Cushman, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 11, 2008
Diuretics as monotherapy or as part of combination therapy for hypertension: an updateMarvin Moser, Domenic Sica, William Cushman, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|September 8, 2011
Thiazide and loop diureticsDomenic A Sica, Barry Carter, William Cushman, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|August 4, 2007
Getting to goal blood pressure: why reserpine deserves a second lookJoshua Barzilay, Richard Grimm, William Cushman, et al.
Journal of Diabetes and Its Complications|August 25, 2022
A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: A revisit to the ACCORD trialHamed Kianmehr, Jingchuan Guo, Yilu Lin, et al.
American Journal of Nephrology|December 20, 2016
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes StudyVasilios Papademetriou, Laura Lovato, Costas Tsioufis, et al.
Diabetes Care|December 15, 2012
Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trialHertzel C Gerstein, Walter T Ambrosius, Ronald Danis, et al.
Pageof 2